The search for an optimal patch material for aortic valve reconstruction (AVR) is an ongoing challenge. In this study, we report our experience of AVR using decellularized bovine pericardial patch material in congenital heart surgery. Data of 40 consecutive patients who underwent AVR using the CardioCel® patch (Admedus Regen Pty Ltd, Perth, WA, Australia) between February 2014 and August 2016 were retrospectively reviewed. The median age of the patients at operation was 9 (2–34) years, and 18 patients were younger than 7 years. Twenty-six patients initially presented with aortic valve insufficiency (AI) and 14 with stenosis. Clinical and echocardiographic data were available until August 2017 for a median postoperative follow-up (FU) of 22 (6–42) months. Nine of 40 (23%) patients experienced an event during FU (death: n = 1, 2.5%; reoperation: n = 8, 20%). Overall, the probability of freedom from reoperation or death was 97 ± 3%, 76 ± 9% and 57 ± 12% at 12, 24 and 36 months of FU, respectively. Reason for reoperation was stenosis in 3 (37.5%) patients, insufficiency in 4 (50%) patients and 1 (12.5%) patient was diagnosed with aortic valve endocarditis. Of the remaining 31 patients, 2 patients are scheduled for reoperation (aortic valve stenosis: n = 1 and AI: n = 1) and 9 patients exhibit worsening of aortic valve function with moderate AI. Freedom from developing combined end point [death/reoperation/moderate degree of aortic valve dysfunction (aortic valve stenosis, AI)] after AVR was 92 ± 5%, 55 ± 9% and 28 ± 9% at 12, 24 and 36 months, respectively. AVR using decellularized bovine pericardial patch material in patients with congenital aortic valve disease show unsatisfactory results within the first 3 years of FU.
1 August 2021 in The Journal of Thoracic and Cardiovascular Surgery
OBJECTIVES: Our goal was to evaluate the impact of the adult congenital heart disease anatomical and physiological (ACHD AP) classification system on the surgical management of Ebstein anomaly (EA) in adult patients. METHODS: From February 2000 through August 2017, data of patients aged at least 16 years, who underwent primary EA surgery, were retrospectively evaluated. The cohort was divided in 2 groups according to their ACHD AP classification: the moderate EA group (IIB, IIC) and the severe EA group (IID). Survival, freedom from reoperation and freedom from occurrence of major adverse advents were estimated. RESULTS: There were 33 patients (21 women, 12 men). Eighteen belonged to the moderate group, 15 to the severe group. There were 12 female patients (80%) in the severe group. Patients in the moderate group were younger than those in the severe group (P = 0.02): 32 ± 12 vs 44 ± 15 years old. Thirty tricuspid valve repairs and 3 replacements were performed. Repair was mainly performed in the moderate group (P = 0.02). Overall survival was 90.1 ± 5.4% at 9 months after the operation and did not change in the later follow-up period. It was 100% for patients in the moderate group and 80.0 ± 10.3% in the severe group (P = 0.07), and 75.0 ± 12.5% for female patients of in the severe group compared to 100% for the remaining patients (P = 0.025). Survival free from major adverse events, including reoperation, at 10 years was 60.0 ± 12.6% in the moderate and 38.1% ± 12.9% in the severe group (P = 0.03). No patient in the moderate group evolved to be in the severe group at late follow-up. CONCLUSION: Adult EA patients should undergo surgery earlier when they are still in the moderate ACHD AP classification.
22 March 2018 in Interactive CardioVascular and Thoracic Surgery
To assess our practice according to the Society of Thoracic Surgeons and the European Association for Cardio-Thoracic Surgery (STS-EACTS) Mortality Score and to the new concept of unit performance. All main procedures carried out in the years 2012–2016 were analysed. The STS-EACTS model-based mortality risk procedure was used to calculate expected mortality. Surgical performance was estimated as the Aristotle complexity score multiplied by hospital survival. Unit performance was defined as surgical performance multiplied by the number of procedures. In total, 2435 procedures were analysed. One hundred and two deaths (95% confidence interval 71–135 deaths) were expected; 43 patients died after operation. Observed mortality divided by expected mortality was 0.42. The ratio ranged from 0.23 (year 2014) to 0.59 (year 2013) and was <0.6 in all STS-EACTS mortality categories. The difference between observed and expected mortality was highly significant: 1.8% vs 4.2% (P-value <0.0001). Observed surgical and unit performances were, higher than expected performances every year. Achieved surgical performance was the highest in year 2012 (7.28 ± 2.54) and the lowest in year 2014 (7.04 ± 2.52). The highest figure of unit performance was achieved in year 2016: 3980 points. The STS-EACTS score, currently recognized as a sound instrument to assess mortality after congenital heart surgery, overestimated postoperative mortality. If these results are confirmed by other centres, the model should be recalibrated to match the current surgical practice. Although surgical performance can evaluate outcome quality, it does not include case volume activity. Unit performance provides this information, and it integrates quality and quantity into a single value.
1 June 2022 in Journal of Cardiothoracic and Vascular Anesthesia